Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Federico Nasroulah, Tudor–Eliade Ciuleanu et al.|The Lancet Oncology|2015Cited by 954
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil TherapyJan H. Beumer, Markus Joerger, Edward Chu et al.|Clinical Pharmacology & Therapeutics|2018Cited by 126
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 StudyAkihito Kawazoe, Reinhard Depenbusch, Rui‐Hua Xu et al.|Journal of Clinical Oncology|2024Cited by 77